Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ImmuCellFRA:IUL +1.22%58 FCF Margin % is 31.79% as of Jun. 2026. GuruFocus rates FRA:IUL with a GF Score™ of 58/100 and a GF Value™ of €5.66 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 957 Biotechnology companies, ImmuCell ranks better than 85.37% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. ImmuCell's Free Cash Flow for the
three
months ended in Jun. 2026 was €1.98 Mil. ImmuCell's Revenue for the
three
months ended in Jun. 2026 was €6.24 Mil. Therefore, ImmuCell's FCF Margin % for the quarter that ended in Jun. 2026 was 31.79%.
The historical data trend for ImmuCell's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:IUL vs COYA, ENTX, BDTX: FCF Margin % Comparison
For the Biotechnology subindustry, ImmuCell's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ImmuCell FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ImmuCell's FCF Margin % distribution charts can be found below:
* The bar in red indicates where ImmuCell's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ImmuCell (FRA:IUL) has a FCF Margin % of 31.79% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on ImmuCell and its competitors. According to the industry distribution chart, ImmuCell ranks #140 out of 957 companies in the Biotechnology industry, placing it in the top 14.6%.
Is ImmuCell's FCF Margin % too high?
ImmuCell's current FCF Margin % is 31.79%. Based on the distribution chart, ImmuCell ranks #140 out of 957 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, ImmuCell has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ImmuCell's FCF Margin % compare to COYA and ENTX?
According to the Biotechnology industry distribution chart, ImmuCell ranks #140 out of 957 companies for FCF Margin %. This places ImmuCell in the top 15% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on ImmuCell and its competitors. ImmuCell's current FCF Margin % is 31.79%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ImmuCell stock overvalued right now?
Based on GuruFocus' analysis, ImmuCell (FRA:IUL) is currently considered Significantly Overvalued. The stock's GF Value™ is €5.66, compared to a current price of €8.30 — trading 46.6% above its estimated fair value. The current FCF Margin % is 31.79%. ImmuCell's overall GF Score™ is 58/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For ImmuCell (FRA:IUL), the current FCF Margin % is 31.79% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ImmuCell (FRA:IUL) Overvalued in 2026?
Based on GuruFocus' analysis, ImmuCell stock appears to be overvalued.
The current stock price of €8.30 is trading 46.6% above its estimated GF Value™ of €5.66.
GuruFocus considers ImmuCell to be Significantly Overvalued.
Key valuation signals for FRA:IUL:
FCF Margin %: 31.79%
GF Value™: €5.66 vs. price of €8.30 (46.6% above fair value)
No single metric tells the full story. See the FRA:IUL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.
58GF Score
Get the complete analysis for FRA:IUL
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:IUL has been successfully added to your 
